| Spread | 0.37 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 85.51 |
| Open* | 86.15 |
| 1-Year Change* | -29.97% |
| Day's Range* | 85.09 - 86.15 |
| 52 wk Range | 88.00-147.66 |
| Average Volume (10 days) | 781.01K |
| Average Volume (3 months) | 14.69M |
| Market Cap | 23.18B |
| P/E Ratio | 7.98 |
| Shares Outstanding | 237.72M |
| Revenue | 7.20B |
| EPS | 12.22 |
| Dividend (Yield %) | N/A |
| Beta | 0.27 |
| Next Earnings Date | Mar 20, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 18, 2024 | 86.15 | 0.63 | 0.74% | 85.52 | 86.40 | 84.95 |
| Apr 17, 2024 | 86.10 | 0.23 | 0.27% | 85.87 | 86.72 | 85.33 |
| Apr 16, 2024 | 85.95 | -0.76 | -0.88% | 86.71 | 87.23 | 85.95 |
| Apr 15, 2024 | 87.54 | 1.79 | 2.09% | 85.75 | 88.90 | 84.96 |
| Apr 12, 2024 | 86.64 | -0.57 | -0.65% | 87.21 | 87.45 | 85.53 |
| Apr 11, 2024 | 86.83 | -1.10 | -1.25% | 87.93 | 89.23 | 86.72 |
| Apr 10, 2024 | 88.40 | -1.25 | -1.39% | 89.65 | 89.95 | 87.55 |
| Apr 9, 2024 | 90.05 | 0.95 | 1.07% | 89.10 | 92.36 | 88.76 |
| Apr 8, 2024 | 89.00 | -0.95 | -1.06% | 89.95 | 90.59 | 89.00 |
| Apr 5, 2024 | 90.05 | 0.61 | 0.68% | 89.44 | 90.52 | 88.95 |
| Apr 4, 2024 | 89.82 | -1.25 | -1.37% | 91.07 | 91.72 | 89.75 |
| Apr 3, 2024 | 90.70 | -0.03 | -0.03% | 90.73 | 91.54 | 89.52 |
| Apr 2, 2024 | 91.27 | -1.66 | -1.79% | 92.93 | 93.02 | 91.26 |
| Apr 1, 2024 | 92.77 | -0.05 | -0.05% | 92.82 | 93.14 | 91.10 |
| Mar 28, 2024 | 91.95 | -0.10 | -0.11% | 92.05 | 93.73 | 91.95 |
| Mar 27, 2024 | 92.73 | 0.60 | 0.65% | 92.13 | 93.49 | 90.72 |
| Mar 26, 2024 | 91.55 | -1.24 | -1.34% | 92.79 | 93.39 | 91.45 |
| Mar 25, 2024 | 92.95 | 2.71 | 3.00% | 90.24 | 93.15 | 90.24 |
| Mar 22, 2024 | 91.92 | 0.44 | 0.48% | 91.48 | 92.06 | 90.63 |
| Mar 21, 2024 | 91.79 | 1.84 | 2.05% | 89.95 | 93.23 | 87.95 |
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, May 6, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 BioNTech SE Earnings Call Q1 2024 BioNTech SE Earnings CallForecast -Previous - |
| Time (UTC) 12:30 | Country US
| Event Q1 2024 BioNTech SE Earnings Release Q1 2024 BioNTech SE Earnings ReleaseForecast -Previous - |
| Friday, May 17, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event BioNTech SE Annual Shareholders Meeting BioNTech SE Annual Shareholders MeetingForecast -Previous - |
| Monday, August 5, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q2 2024 BioNTech SE Earnings Call Q2 2024 BioNTech SE Earnings CallForecast -Previous - |
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 17310.6 | 18976.7 | 482.325 | 108.589 | 127.575 |
| Revenue | 17310.6 | 18976.7 | 482.325 | 108.589 | 127.575 |
| Cost of Revenue, Total | 2995 | 2911.5 | 59.333 | 17.361 | 13.69 |
| Gross Profit | 14315.6 | 16065.2 | 422.992 | 91.228 | 113.885 |
| Total Operating Expense | 4667.9 | 3692.9 | 564.742 | 290.107 | 181.429 |
| Selling/General/Admin. Expenses, Total | 544.2 | 328.9 | 103.457 | 44.45 | 27.07 |
| Research & Development | 1487.7 | 916.3 | 614.837 | 197.893 | 124.728 |
| Depreciation / Amortization | 49.3 | 40.2 | 35.296 | 32.388 | 20.617 |
| Unusual Expense (Income) | -1.4 | -137.2 | 0 | ||
| Other Operating Expenses, Total | -65 | -1.1 | -248.181 | -1.985 | -4.676 |
| Operating Income | 12642.7 | 15283.8 | -82.417 | -181.518 | -53.854 |
| Interest Income (Expense), Net Non-Operating | 314.1 | -215.5 | -60.337 | 2.404 | 6.24 |
| Other, Net | -2.7 | -21.9 | -3.048 | -0.326 | -0.048 |
| Net Income Before Taxes | 12954.1 | 15046.4 | -145.802 | -179.44 | -47.662 |
| Net Income After Taxes | 9434.4 | 10292.5 | 15.198 | -179.172 | -48.262 |
| Minority Interest | 0 | 0.116 | 0.243 | ||
| Net Income Before Extra. Items | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Net Income | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Income Available to Common Excl. Extra. Items | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Income Available to Common Incl. Extra. Items | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Diluted Net Income | 9434.4 | 10292.5 | 15.198 | -179.056 | -48.019 |
| Diluted Weighted Average Shares | 249.8 | 259.7 | 253.3 | 210.654 | 226.262 |
| Diluted EPS Excluding Extraordinary Items | 37.7678 | 39.6323 | 0.06 | -0.85 | -0.21223 |
| Diluted Normalized EPS | 37.7637 | 39.2709 | 0.06 | -0.85 | -0.21223 |
| Interest Expense (Income) - Net Operating | -341.9 | -365.7 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 167.7 | 1277 | 4278.3 | 3461.2 | 3196.5 |
| Revenue | 167.7 | 1277 | 4278.3 | 3461.2 | 3196.5 |
| Cost of Revenue, Total | 162.9 | 96 | 183.5 | 752.8 | 764.6 |
| Gross Profit | 4.8 | 1181 | 4094.8 | 2708.4 | 2431.9 |
| Total Operating Expense | 731 | 622.6 | 985.4 | 1073.7 | 986.9 |
| Selling/General/Admin. Expenses, Total | 140.8 | 131.6 | 137.5 | 153.8 | 147.8 |
| Research & Development | 359.6 | 319.3 | 496.5 | 328.2 | 388 |
| Depreciation / Amortization | 13.8 | 14.7 | 13.3 | 13.6 | 11.6 |
| Interest Expense (Income) - Net Operating | 58.6 | 74.6 | 166.5 | -166.4 | -287.3 |
| Unusual Expense (Income) | -1.2 | -0.2 | 0 | ||
| Other Operating Expenses, Total | -4.7 | -13.6 | -10.7 | -8.1 | -37.8 |
| Operating Income | -563.3 | 654.4 | 3292.9 | 2387.5 | 2209.6 |
| Interest Income (Expense), Net Non-Operating | 152.4 | 53.2 | -120.3 | 56.7 | 109.7 |
| Other, Net | -1.3 | 0.1 | 0 | -0.1 | 0 |
| Net Income Before Taxes | -412.2 | 707.7 | 3172.6 | 2444.1 | 2319.3 |
| Net Income After Taxes | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Net Income Before Extra. Items | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Net Income | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Income Available to Common Excl. Extra. Items | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Income Available to Common Incl. Extra. Items | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Diluted Net Income | -190.4 | 502.2 | 2278.7 | 1784.9 | 1672 |
| Diluted Weighted Average Shares | 241.013 | 244.97 | 244.761 | 255.716 | 259.225 |
| Diluted EPS Excluding Extraordinary Items | -0.79 | 2.05005 | 9.3099 | 6.98 | 6.45 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.79 | 2.05005 | 9.30638 | 6.97943 | 6.45 |
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 21922 | 15072.3 | 1666.9 | 560.151 | 448.961 |
| Cash and Short Term Investments | 14064.5 | 2074.3 | 1347.44 | 520.829 | 411.831 |
| Cash | 13875.1 | 1692.7 | 1210.21 | 519.149 | 411.495 |
| Short Term Investments | 189.4 | 381.6 | 137.234 | 1.68 | 0.336 |
| Total Receivables, Net | 7146 | 12382.1 | 170.521 | 20.205 | 28.44 |
| Accounts Receivable - Trade, Net | 7145.6 | 12381.7 | 165.468 | 11.913 | 18.938 |
| Total Inventory | 439.6 | 502.5 | 64.12 | 11.722 | 5.789 |
| Prepaid Expenses | 29.845 | 0.351 | 0.155 | ||
| Other Current Assets, Total | 271.9 | 113.4 | 54.967 | 7.044 | 2.746 |
| Total Assets | 23279.1 | 15830.8 | 2318.62 | 797.647 | 652.986 |
| Property/Plant/Equipment, Total - Net | 821.1 | 520.4 | 325.956 | 148.062 | 115.965 |
| Property/Plant/Equipment, Total - Gross | 937.4 | 594.6 | 384.288 | 197.345 | 152.617 |
| Accumulated Depreciation, Total | -116.3 | -74.2 | -58.332 | -49.285 | -36.652 |
| Goodwill, Net | 61.2 | 57.8 | 53.697 | 2.978 | 0.534 |
| Intangibles, Net | 158.5 | 144.6 | 109.793 | 86.456 | 87.508 |
| Long Term Investments | 80.2 | 21.3 | 0 | 0.018 | |
| Other Long Term Assets, Total | 236.1 | 14.4 | 162.278 | 0 | |
| Total Current Liabilities | 2950.6 | 3481.6 | 606.014 | 138.142 | 126.121 |
| Accounts Payable | 204.1 | 160 | 102.288 | 20.498 | 41.721 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 36 | 129.9 | 6.127 | 3.485 | 8.266 |
| Other Current Liabilities, Total | 2710.5 | 3191.7 | 497.599 | 114.159 | 76.134 |
| Total Liabilities | 3223.5 | 3937.1 | 946.774 | 304.155 | 386.833 |
| Total Long Term Debt | 176.2 | 171.6 | 231.047 | 68.904 | 5.6 |
| Long Term Debt | 2.1 | 17.9 | 153.016 | 14.777 | 5.6 |
| Minority Interest | 0 | 0.847 | |||
| Other Liabilities, Total | 90.5 | 217.2 | 109.432 | 97.109 | 254.265 |
| Total Equity | 20055.6 | 11893.7 | 1371.85 | 493.492 | 266.153 |
| Common Stock | 248.6 | 246.3 | 246.31 | 232.304 | 193.296 |
| Retained Earnings (Accumulated Deficit) | 19812.3 | 11651.2 | 1130.32 | 266.713 | 72.857 |
| Total Liabilities & Shareholders’ Equity | 23279.1 | 15830.8 | 2318.62 | 797.647 | 652.986 |
| Total Common Shares Outstanding | 243.215 | 242.521 | 241.521 | 226.78 | 226.262 |
| Capital Lease Obligations | 174.1 | 153.7 | 78.031 | 54.127 | |
| Treasury Stock - Common | -5.3 | -3.8 | -4.789 | -5.525 | |
| Deferred Income Tax | 6.2 | 66.7 | 0.281 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 18749.1 | 19213.9 | 20086.1 | 21922 | 21268.8 |
| Cash and Short Term Investments | 15749.1 | 15557.3 | 12501.9 | 14064.5 | 13428.5 |
| Cash | 13495.8 | 14166.6 | 12143.9 | 13875.1 | 13423.7 |
| Short Term Investments | 2253.3 | 1390.7 | 358 | 189.4 | 4.8 |
| Total Receivables, Net | 2298.1 | 2995.4 | 6988.8 | 7146 | 7309.8 |
| Accounts Receivable - Trade, Net | 2008.8 | 2663.8 | 6456.2 | 7145.6 | 7309.4 |
| Total Inventory | 415.7 | 448.9 | 424.1 | 439.6 | 294.8 |
| Other Current Assets, Total | 286.2 | 212.3 | 171.3 | 271.9 | 235.7 |
| Total Assets | 22207.2 | 22225.6 | 22079 | 23279.1 | 22660.6 |
| Property/Plant/Equipment, Total - Net | 925.9 | 894 | 847.6 | 821.1 | 760.5 |
| Intangibles, Net | 665.5 | 501.4 | 378.6 | 219.7 | 226.2 |
| Other Long Term Assets, Total | 208.4 | 242 | 249.9 | 236.1 | 352.3 |
| Total Current Liabilities | 1807.2 | 1819 | 1550.9 | 2950.6 | 3957.7 |
| Accounts Payable | 222.7 | 228.6 | 29.9 | 204.1 | 296.5 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 40 | 38.6 | 37.4 | 36 | 37 |
| Other Current Liabilities, Total | 1544.5 | 1551.8 | 1483.6 | 2710.5 | 3624.2 |
| Total Liabilities | 2340.4 | 2319.1 | 1813.7 | 3223.5 | 4294.3 |
| Total Long Term Debt | 161.9 | 167.1 | 172.4 | 176.2 | 237 |
| Long Term Debt | 161.9 | 167.1 | 172.4 | 176.2 | 237 |
| Deferred Income Tax | 43.1 | 4.5 | 5.3 | 6.2 | 7 |
| Other Liabilities, Total | 328.2 | 328.5 | 85.1 | 90.5 | 92.6 |
| Total Equity | 19866.8 | 19906.5 | 20265.3 | 20055.6 | 18366.3 |
| Common Stock | 248.6 | 248.6 | 248.6 | 248.6 | 248.6 |
| Retained Earnings (Accumulated Deficit) | 19629 | 19666.7 | 20024.3 | 19812.3 | 18128 |
| Treasury Stock - Common | -10.8 | -8.8 | -7.6 | -5.3 | -10.3 |
| Total Liabilities & Shareholders’ Equity | 22207.2 | 22225.6 | 22079 | 23279.1 | 22660.6 |
| Total Common Shares Outstanding | 237.715 | 239.771 | 240.99 | 243.215 | 242.521 |
| Long Term Investments | 1292.7 | 1374.3 | 516.8 | 80.2 | 52.8 |
| Goodwill, Net | 365.6 |
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 12954.1 | 15046.4 | -145.802 | -179.44 | -47.662 |
| Cash From Operating Activities | 13577.4 | 889.7 | -13.474 | -198.537 | -58.877 |
| Cash From Operating Activities | 123.3 | 75.2 | 38.744 | 33.896 | 21.984 |
| Non-Cash Items | 247.6 | -32.6 | 188.487 | 31.109 | 7.943 |
| Cash Taxes Paid | 4222.1 | 3457.9 | -0.378 | -0.122 | 0.304 |
| Cash Interest Paid | 21.5 | 12.2 | 3.628 | 2.044 | 1.769 |
| Changes in Working Capital | 252.4 | -14199.3 | -94.903 | -84.102 | -41.142 |
| Cash From Investing Activities | -35.3 | -566.1 | -144.848 | -77.115 | -66.452 |
| Capital Expenditures | -363.3 | -154 | -85.446 | -71.08 | -67.157 |
| Other Investing Cash Flow Items, Total | 328 | -412.1 | -59.402 | -6.035 | 0.705 |
| Cash From Financing Activities | -1419.3 | 94.2 | 894.725 | 383.29 | 365.177 |
| Issuance (Retirement) of Stock, Net | -875.9 | 160.9 | 753.007 | 375.351 | 361.725 |
| Issuance (Retirement) of Debt, Net | -59.1 | -66.7 | 141.718 | 7.939 | 3.452 |
| Foreign Exchange Effects | 59.6 | 64.7 | -45.343 | 0.016 | -0.459 |
| Net Change in Cash | 12182.4 | 482.5 | 691.06 | 107.654 | 239.389 |
| Total Cash Dividends Paid | -484.3 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 707.7 | 12954.1 | 9781.5 | 7337.4 | 5018.1 |
| Cash From Operating Activities | -677.4 | 13577.4 | 12748.2 | 7969.3 | 4050.2 |
| Cash From Operating Activities | 31.4 | 123.3 | 94.3 | 60.8 | 27.6 |
| Non-Cash Items | 54 | 247.6 | -267.6 | -438 | -197 |
| Cash Taxes Paid | 844.9 | 4222.1 | 2834.7 | 2081.4 | 1290 |
| Cash Interest Paid | 1.2 | 21.5 | 16.5 | 12.2 | 6.4 |
| Changes in Working Capital | -1470.5 | 252.4 | 3140 | 1009.1 | -798.5 |
| Cash From Investing Activities | -735.4 | -35.3 | 125.7 | 209 | 287.4 |
| Capital Expenditures | -54.8 | -363.3 | -218.8 | -136.2 | -60.8 |
| Other Investing Cash Flow Items, Total | -680.6 | 328 | 344.5 | 345.2 | 348.2 |
| Cash From Financing Activities | -291.3 | -1419.3 | -1354.6 | -701.2 | 80.3 |
| Issuance (Retirement) of Debt, Net | -9.3 | -59.1 | -50.1 | -40.5 | -30.2 |
| Foreign Exchange Effects | -27.1 | 59.6 | 211.7 | 165 | 53.5 |
| Net Change in Cash | -1731.2 | 12182.4 | 11731 | 7642.1 | 4471.4 |
| Issuance (Retirement) of Stock, Net | -282 | -875.9 | -820.2 | -176.4 | 110.5 |
| Total Cash Dividends Paid | -484.3 | -484.3 | -484.3 |
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Founded in 2008, BioNTech is an innovative biotechnology company from Germany, specialising in the research, development and producing of active individualised immunotherapies. The company adheres to a patient-specific approach to treatment of serious diseases, such as cancer.
BioNTech shares a vision that every patient’s tumour is unique. It means that each patient’s treatment should be individualised. To implement the scientists’ ideas into practice, BioNTech has developed pioneering therapeutics for cancer and other rare and infectious diseases.
Headquartered in Mainz, Germany, the company is aimed at becoming the world’s leading biotechnology company for individialised cancer treatment. By 2020, BioNTech had more than 440 patients treated across 17 tumour types. The company has more than 1,300 employees and seven pharmaceutical partners.
In August 2018, the company partnered with the US pharmaceutical giant Pfizer Inc to develop mRNA-based vaccines for preventing influenza. In September 2019, BioNTech started working on the development of tuberculosis and HIV programmes and preclinical vaccine and immunotherapy candidates for the prevention of tuberculosis and HIV infections under an agreement with the Bill & Melinda Gates Foundation.
BioNTech stock floated on the NASDAQ stock exchange through a $150m initial public offering (IPO) in October 2019. Since then the BNTX stock quote has been traded on the US market.
In November 2020, BioNTech and Pfizer triggered the strongest wave of optimism on the stock market after they announced that their Covid-19 vaccine showed 90 per cent effectiveness during the phase-three clinical trials. The BioNTech share price soared 14 per cent the day after the announcement.
In 2019, BioNTech reported total revenues of about €109m. According to the estimates from Morgan Stanley, BioNTech and Pfizer can make around $13bn from vaccine sales, getting $6.5bn each if these estimates are correct.
Looking closely at the BioNTech stock price chart in 2020, we can see that BNTX stock has been trading in a range of $18.60-$115. Since the large sell-off in March 2020, the BioNTech SE (BNTX) stock quote grew from $28.55 on March 12, 2020, to $112.76 on November 10, 2020, which is a growth of 294 per cent.
Follow the BioNTech share price live on our interactive share price chart and build your own forecast for the famous German biotechnology company. Follow the latest BioNTech share news and spot the best levels to open profitable CFD trades at Capital.com.
| Industry: | Bio Therapeutic Drugs |
An der Goldgrube 12
MAINZ
RHEINLAND-PFALZ 55131
DE
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Invest in BioNTech shares, other major stocks, indices, forex, commodities and cryptocurrencies with CFDs at Capital.com’s award-winning platform. No commission. FCA and CySEC regulated. Available on web and mobile. AI technology.
Learn more about BioNtech SE
Join the 610,000+ traders worldwide that chose to trade with Capital.com
